Non-invasive continuous glucose monitoring device maker Echo Therapeutics, Inc. tells us it has achieved its wireless mobile communication milestone, making it now possible for its continuous glucose sensor to transmit data to any mobile platform.
The last eighteen months have been pretty turbulent for the remote glucose monitoring specialist, but things have recently taken a turn for the better, culminating in this achievement, which means the company is on the road to morphing its hospital-based medical system into a consumer product in both the wearable-health and diabetes segments.
Echo’s communications architecture means its utility extends to wireless compatibility with mobile devices, including smartphones, using Bluetooth Low Energy (BLE) connectivity, keeping power consumption and cost to a minimum. The company also developed a mobile application to demonstrate the transmitted glucose information on a smartphone. This new system leverages the progress made recently in both the skin preparation and glucose sensing technology and is currently being evaluated using in-house clinical feasibility studies. The Company received Institutional Review Board (IRB) approval for the clinical trial protocol and has commenced testing of these advancements.
“This milestone, announced in our recent webcast, is an important and critical first step forward for Echo as the application of our continuous glucose monitoring technology transitions to a consumer product. Importantly, the smartphone connectivity and mobile application now provides the ability to demonstrate our technology to potential partners,” said Scott W. Hollander, Echo’s President and CEO. “We look forward to updating shareholders with future advancements in the achievement of our goal of combining an advanced glucose sensor system with wireless and low-power communications into a small and flexible package.”
Source: PR Newswire